204 results on '"Bowker, Karen"'
Search Results
2. Clinical diagnosis and treatment of common respiratory tract infections in relation to microbiological profiles in rural health facilities in China: implications for antibiotic stewardship
3. Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection
4. Studies on antimicrobial pharmacodynamics using in vitro methodologies
5. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments
6. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection
7. Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa
8. Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection
9. Limited phylogenetic overlap between fluoroquinolone-resistant Escherichia coli isolated on dairy farms and those causing bacteriuria in humans living in the same geographical region
10. Prevalence of antibiotic resistance in Escherichia coli isolated from urine samples routinely referred by general practitioners in a large urban centre in south-west England
11. Additional file 1 of Clinical diagnosis and treatment of common respiratory tract infections in relation to microbiological profiles in rural health facilities in China: implications for antibiotic stewardship
12. Additional file 3 of Clinical diagnosis and treatment of common respiratory tract infections in relation to microbiological profiles in rural health facilities in China: implications for antibiotic stewardship
13. Additional file 2 of Clinical diagnosis and treatment of common respiratory tract infections in relation to microbiological profiles in rural health facilities in China: implications for antibiotic stewardship
14. Colistin susceptibility testing: time for a review
15. Low Prevalence of Antibiotic Resistance and High Level of Antibiotic Consumption in Rural China: Interdisciplinary Study
16. Clinical diagnosis and treatment of common respiratory tract infections in relation to microbiological profiles in rural health facilities in China: implications for antibiotic stewardship
17. Clinical Symptoms and Treatment of Common Respiratory Tract Infections in Relation to Microbiological Profiles in Rural Health Facilities in China: Implications for Antibiotic Stewardship
18. The pharmacodynamics of fosfomycin against Staphylococcus aureus studied in an in vitro model of infection
19. Comment on: Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections
20. Comparative evaluation of eight in vitro pharmacodynamic models of infection: Activity of moxifloxacin against Escherichia coli and Streptococcus pneumoniae as an exemplary example
21. Continuous Infusion of β-Lactam Antibiotics
22. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection
23. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection
24. Theatre shoes - a link in the common pathway of postoperative wound infection?
25. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system
26. Discrepancy between viable counts and light output as viability measurements, following ciprofloxacin challenge of self-bioluminescent Pseudomonas aeruginosa biofilms
27. The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model
28. Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
29. Pathways to optimising antibiotic use in rural China: identifying key determinants in community and clinical settings, a mixed methods study protocol
30. Characterisation of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017-2018
31. Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures
32. Vancomycin-resistant Staphylococcus aureus
33. Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017-18.
34. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection
35. Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection
36. Prediction of Fluoroquinolone Susceptibility Directly from Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass Spectrometry To Identify Mutant Genotypes
37. Prediction of fluoroquinolone susceptibility directly from whole genome sequence data using liquid chromatography-tandem mass spectrometry to identify mutant genotypes
38. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime againstβ-lactamase-producing Enterobacteriaceae studied in anin vitromodel of infection
39. In Vitro Models, In Vivo Models, and Phaimacokinetics: What Can We Learn from In Vitro Models?
40. Pharmacodynamics of inhaled amikacin studied in an in vitro pharmacokinetic model of infection
41. Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in anin vitropharmacokinetic model of infection
42. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection
43. Pharmacodynamics of Ceftaroline against Staphylococcus aureus Studied in anIn VitroPharmacokinetic Model of Infection
44. Pharmacodynamics of the Antibacterial Effect of and Emergence of Resistance to Doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an In Vitro Pharmacokinetic Model
45. Reply to “Breakthrough Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae during Combination Therapy with Colistin and Tigecycline”
46. Bactericidal Activity of Multiple Combinations of Tigecycline and Colistin against NDM-1-Producing Enterobacteriaceae
47. Pharmacodynamics of Razupenem (PZ601) Studied in an In Vitro Pharmacokinetic Model of Infection
48. Reducing the Risk of Surgical Site Infection: A Case Controlled Study of Contamination of Theatre Clothing
49. Pharmacodynamics of Telavancin Studied in an In Vitro Pharmacokinetic Model of Infection
50. Bacterial Strain-to-Strain Variation in Pharmacodynamic Index Magnitude, a Hitherto Unconsidered Factor in Establishing Antibiotic Clinical Breakpoints
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.